Abstract
Abstract:
Antibiotic resistance has emerged as a critical threat for the treatment of bacterial ocular infections. To address the critical need for novel therapeutics, antibiotic drug repurposing holds significant promise. As such, examples of existing FDA-approved drugs currently under development for new applications, novel combinations, and improved delivery systems are discussed.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference41 articles.
1. The persistent dilemma of microbial keratitis: global burden, diagnosis, and antimicrobial resistance;Ung;Surv Ophthalmol.,2019
2. Infectious keratitis: an update on epidemiology, causative microorganisms, risk factors, and antimicrobial resistance;Ting;Eye,2021
3. A 10-year analysis of microbiological profiles of microbial keratitis: the North East England Study;Ting;Eye,2018
4. Shifting trends in bacterial keratitis in Toronto: an 11-year review;Lichtinger;Ophthalmology,2012
5. Microbial keratitis;Keay;Ophthalmology,2006